The user regrets stopping finasteride and minoxidil due to increased hair loss. They have resumed these treatments and are considering a hair transplant.
Pelage Pharmaceuticals' PP405 is discussed with skepticism about its effectiveness in hair regrowth, with some users expressing doubt and others hopeful but cautious. Treatments like finasteride are mentioned as current options, but there's a general sentiment that a cure for hair loss is not imminent.
RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safety profiles.
Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.
Long-term finasteride users often experience periodic hair shedding due to natural hair cycles, even after several years of use. Some consider switching to dutasteride, but concerns about side effects and the effectiveness of finasteride remain common.
The user is experiencing significant hair loss after switching from finasteride to dutasteride for five months. Suggestions include that the hair loss might be a normal shedding phase, with some recommending continuing the treatment for up to 24 months or considering alternatives like RU58841.
The user is using finasteride and topical minoxidil for hair loss after previously trying them separately without success. They are experiencing a shedding phase but are committed to the treatment.
Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.
PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
An 18-year-old restarted using topical minoxidil consistently after noticing diffuse thinning and is experiencing increased shedding with black bulbs. Users suggest that shedding is common and may stop with consistent use, but the black bulbs could indicate a strong response to minoxidil.
Maintaining good hair density is more important than preventing a receding hairline, as it can enhance a mature look. Treatments discussed include finasteride, minoxidil, dutasteride, and RU58841.
Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.
A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.
Switching from liquid to foam minoxidil may cause mild shedding, possibly due to differences in absorption. Returning to the original liquid formulation typically stabilizes shedding within a few weeks.
OP switched from finasteride to dutasteride due to hair loss, but after 5 months, they are experiencing diffuse thinning and scalp issues. They are considering additional treatments like RU58841 and are using minoxidil, essential oils, and keto shampoo to manage symptoms.
The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.
A 52-year-old with Norwood 6 hair loss shows progress after 5 months using topical dutasteride, LLLT, copper peptides, Ulo serum, Minoxidil, cetirizine, and microneedling. Native hair is regrowing from vellus to terminal, with increased density in previously bald areas.
The user has tried various treatments for hair loss, including finasteride, dutasteride, RU58841, Pyrilutamide, and several topical growth factors, but continues to experience a receding hairline and thinning. Despite maintaining a healthy lifestyle, the user is unsure why these treatments are ineffective and seeks advice on the underlying cause.
The user experienced hair repigmentation and attributes improvements in hair and overall health to a carnivore diet, Boron, and Selenium supplementation. They stopped using finasteride after 20 years, noticed increased testosterone and libido, and observed hair regrowth with RU58841.
Breezula is seen as a potential future treatment for hair loss, but its release is uncertain and current data is limited. Other treatments like GT20026 and pyrilutamide are discussed, but skepticism remains about their effectiveness compared to established options like finasteride and minoxidil.
New hair loss treatments like GT20029, Clascoterone, and PP405 are being discussed, with concerns about how to apply multiple topicals alongside existing treatments like minoxidil and finasteride. Suggestions include creating a routine, mixing treatments, or minimizing redundancy in treatment stacks.
Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
Hair loss treatments discussed include microneedling, minoxidil, tretinoin, finasteride, dutasteride, pumpkin seeds, saw palmetto, and scalp massage. The consensus is that finasteride or dutasteride is necessary for significant regrowth, while other methods may only slow hair loss.
The user experienced hair shedding after starting finasteride every other day and minoxidil nightly for nine months, with the best hair density in June but shedding since then. They also use Nizoral shampoo twice a week and are concerned about libido effects from daily finasteride use.
The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.
Finasteride and dutasteride are discussed for hair loss, with concerns about their effects on neurosteroids and potential side effects like depression. Alternatives like topical estrogen and lifestyle changes are considered, with varying opinions on mental health and hair regrowth.
Alcohol consumption can trigger hair shedding and affect hair treatment effectiveness, especially in those with autoimmune diseases. Treatments mentioned include RU58841, oral minoxidil, and stemoxydine, with finasteride also noted by another user.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
After a year and a half of using oral minoxidil and dutasteride with no regrowth, OP started topical minoxidil, microneedling, supplements, caffeine shampoo, and scalp massages, leading to new baby hairs. OP feels hopeful seeing regrowth despite initial shedding and stress.